|
Market Closed -
Other stock markets
|
After hours 01:44:34 | |||
| 98.93 USD | -0.79% |
|
98.97 | +0.04% |
| 06:30pm | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 04:29pm | Saskatchewan adds Capvaxive to publicly funded adult immunization program | RE |
| Capitalization | 248B 213B 200B 186B 343B 22,313B 374B 2,331B 903B 10,535B 929B 909B 38,598B | P/E ratio 2025 * |
12.9x | P/E ratio 2026 * | 13.4x |
|---|---|---|---|---|---|
| Enterprise value | 273B 235B 220B 205B 378B 24,598B 412B 2,569B 995B 11,614B 1,024B 1,002B 42,549B | EV / Sales 2025 * |
4.21x | EV / Sales 2026 * | 3.84x |
| Free-Float |
70.67% | Yield 2025 * |
3.24% | Yield 2026 * | 3.39% |
Last Transcript: Merck & Co., Inc.
| 1 day | -0.81% | ||
| 1 week | -2.85% | ||
| Current month | -5.63% | ||
| 1 month | +14.04% | ||
| 3 months | +17.65% | ||
| 6 months | +24.71% | ||
| Current year | -0.55% |
| 1 week | 97.81 |  | 103.09 |
| 1 month | 85.8 | | 105.84 |
| Current year | 73.31 | | 105.84 |
| 1 year | 73.31 | | 105.84 |
| 3 years | 73.31 | | 134.63 |
| 5 years | 70.89 | | 134.63 |
| 10 years | 47.97 | | 134.63 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 58 | 01/07/2021 |
| Director of Finance/CFO | 56 | 01/04/2021 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/08/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 65 | 27/11/2007 |
Patricia Russo
BRD | Director/Board Member | 72 | 01/09/1995 |
Robert Davis
CHM | Chairman | 58 | 01/12/2022 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 14.34% | 303 M€ | -21.86% | - |
| 5.61% | 26 M€ | +11.85% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.79% | -2.85% | -4.68% | -10.75% | 248B | |
| -1.26% | -5.70% | +24.14% | +168.32% | 905B | |
| -0.15% | -1.81% | +34.77% | +13.78% | 487B | |
| -1.31% | -0.88% | +26.36% | +34.42% | 400B | |
| +2.19% | +3.35% | +23.62% | +5.48% | 330B | |
| -0.10% | -2.83% | +27.45% | +20.61% | 281B | |
| -0.41% | +2.07% | +18.74% | +24.32% | 255B | |
| -3.42% | -5.68% | -61.94% | -32.73% | 214B | |
| -2.63% | -4.82% | +15.70% | +12.49% | 178B | |
| -0.02% | -2.53% | +33.78% | +35.45% | 150B | |
| Average | -0.76% | -2.37% | +13.79% | +27.14% | 344.69B | |
| Weighted average by Cap. | -0.70% | -2.83% | +18.28% | +53.50% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 64.76B 55.75B 52.33B 48.65B 89.67B 5,839B 97.83B 610B 236B 2,757B 243B 238B 10,099B | 68.2B 58.71B 55.12B 51.23B 94.44B 6,149B 103B 642B 249B 2,903B 256B 251B 10,636B |
| Net income | 19.47B 16.76B 15.73B 14.63B 26.96B 1,755B 29.41B 183B 70.99B 829B 73.07B 71.51B 3,036B | 18.39B 15.83B 14.86B 13.82B 25.47B 1,658B 27.79B 173B 67.07B 783B 69.03B 67.56B 2,868B |
| Net Debt | 25.34B 21.81B 20.48B 19.03B 35.09B 2,284B 38.28B 239B 92.4B 1,079B 95.1B 93.07B 3,952B | 14.67B 12.63B 11.86B 11.02B 20.32B 1,323B 22.17B 138B 53.51B 625B 55.08B 53.9B 2,288B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/12/25 | 98.93 $ | -0.79% | 12,680,104 |
| 05/12/25 | 99.72 $ | -1.16% | 16,430,388 |
| 04/12/25 | 100.89 $ | -1.35% | 12,770,712 |
| 03/12/25 | 102.27 $ | +1.23% | 12,541,641 |
| 02/12/25 | 101.03 $ | -0.79% | 11,794,980 |
Delayed Quote Nyse, December 09, 2025 at 01:01 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition